b
r
c
cat
live
area
canin
human
leishmaniosi
due
leishmania
infantum
endem
may
becom
infect
may
develop
antileishmania
antibodi
studi
clinic
normal
cat
cutan
andor
system
sign
live
endem
area
previous
examin
infect
l
infantum
use
pcr
four
differ
tissu
serolog
test
presenc
antileishmania
igg
ifat
elisa
igm
ifat
aim
compar
result
ifat
elisa
pcr
investig
possibl
associ
seroposit
leishmania
spp
signal
live
condit
season
sampl
health
statu
cat
seroposit
infecti
agent
low
concentr
antileishmania
igg
detect
ifat
cat
elisa
wherea
antileishmania
igm
detect
ifat
disagr
result
ifat
elisa
antileishmania
igg
p
serolog
test
pcr
p
diagnost
sensit
serolog
test
use
pcr
gold
standard
low
elisa
ifat
antileishmania
igm
specif
diagnost
sensit
serolog
test
could
improv
chang
cutoff
valu
seroposit
leishmania
spp
associ
signal
live
condit
season
sampl
health
statu
cat
seroposit
felin
leukemia
viru
felin
immunodefici
viru
felin
coronaviru
toxoplasma
gondii
bartonella
hensela
conclus
low
sensit
high
specif
two
evalu
serolog
test
elisa
antileishmania
igg
ifat
antileishmania
igm
may
useless
popul
screen
test
valuabl
diagnos
felin
infect
l
infantum
ifat
antileishmania
igm
posit
cat
result
ifat
elisa
antileishmania
igg
disagre
p
igg
disagre
result
pcr
leishmanios
caus
protozoan
parasit
genu
leishmania
endem
least
countri
leishmania
speci
infect
dog
andor
human
also
infect
cat
bonfantegarrido
et
al
craig
et
al
da
silva
et
al
hatam
et
al
pennisi
et
al
poli
et
al
schubach
et
al
et
al
souza
et
al
trainor
et
al
although
dog
consid
main
domest
peridomest
reservoir
zoonot
leishmaniosi
caus
l
infantum
synonym
l
chagasi
baneth
et
al
cat
may
also
implic
transmiss
cycl
parasit
addit
primari
secondari
reservoir
may
accident
host
maia
campino
mancianti
maroli
et
al
last
year
sever
report
symptomat
felin
leishmaniosi
due
l
infantum
european
countri
canin
diseas
endem
sick
cat
serolog
leishmaniaspecif
igg
found
use
diagnost
test
grevot
et
al
et
al
et
al
navarro
et
al
ozon
et
al
pennisi
pennisi
et
al
pennisi
et
al
poli
et
al
time
numer
serolog
survey
base
mainli
indirect
immunofluoresc
antibodi
test
ifat
enzymelink
immunosorb
assay
elisa
less
commonli
direct
agglutin
test
western
blot
antileishmania
igg
antibodi
publish
et
al
ayllon
et
al
bresciani
et
al
cardoso
et
al
diakou
et
al
duart
et
al
maia
et
al
maia
et
al
et
al
et
al
moreno
et
al
nasereddin
et
al
pennisi
poli
et
al
ramo
et
al
sherri
et
al
solanogallego
et
al
vita
et
al
result
studi
diverg
even
area
seropreval
rate
rang
variat
may
attribut
differ
studi
felin
popul
serolog
test
employ
cutoff
valu
howev
serolog
misclassif
falseposit
falseneg
may
offer
addit
explan
discrep
among
survey
consid
poor
correl
serolog
molecular
detect
l
infantum
pcr
ayllon
et
al
et
al
pennisi
also
presenc
signific
antileishmania
igm
antibodi
report
survey
previous
shown
l
infantum
dna
detect
clinic
normal
cat
cat
variou
cutan
andor
system
clinic
sign
live
endem
region
result
pcr
blood
skin
biopsi
bone
marrow
conjunctiva
combin
chatzi
et
al
aim
present
studi
examin
cat
presenc
antileishmania
igg
ifat
elisa
igm
ifat
antibodi
b
compar
result
ifat
elisa
pcr
c
investig
possibl
associ
seroposit
leishmania
spp
signal
live
condit
season
sampl
health
statu
cat
seroposit
infecti
agent
includ
felin
leukemia
viru
felv
felin
immunodefici
viru
fiv
felin
coronaviru
fcv
toxoplasma
gondii
bartonella
hensela
total
cat
live
thessali
n
macedonia
n
prefectur
greec
canin
leishmaniosi
due
l
infantum
endem
athanasi
et
al
leontid
et
al
sampl
previous
describ
chatzi
et
al
cat
least
old
histori
leishmaniosi
administr
drug
known
antileishmania
immunemodul
activ
handl
anim
complianc
european
commun
council
direct
state
law
experiment
protocol
approv
state
author
licens
nr
signal
histor
data
breed
age
sex
length
haircoat
live
condit
live
area
presenc
lush
veget
within
radiu
resid
reduc
appetit
diarrhea
day
examin
vomit
last
week
examin
collect
use
standard
form
follow
thorough
physic
examin
special
attent
paid
cutan
ocular
system
sign
report
clinic
case
felin
leishmaniosi
coelho
et
al
grevot
et
al
et
al
leiva
et
al
navarro
et
al
pennisi
et
al
poli
et
al
et
al
sobrinho
et
al
vide
et
al
vita
et
al
cat
subsequ
assign
two
group
group
cat
n
clinic
normal
wherea
group
b
cat
n
present
variou
dermatolog
ocular
andor
system
clinic
sign
chatzi
et
al
also
cat
consid
infect
l
infantum
result
convent
pcr
andread
et
al
blood
skin
biopsi
bone
marrow
andor
conjunctiva
posit
noninfect
result
pcr
neg
four
tissu
sampl
chatzi
et
al
blood
sampl
obtain
cat
sera
store
c
analyz
control
serum
sampl
obtain
clinic
normal
n
sick
n
cat
origin
texa
usa
leishmaniosi
due
l
infantum
endem
use
establish
ifat
elisa
cutoff
valu
quinnel
et
al
solanogallego
et
al
result
control
serum
sampl
use
establish
cutoff
valu
taken
account
calcul
specif
serolog
ifat
use
measur
antileishmania
igg
igm
titer
group
group
b
control
serum
sampl
slide
coat
promastigot
l
infantum
strain
greek
origin
sideri
et
al
provid
nation
refer
center
leishmaniasi
hellen
pasteur
institut
antifelin
igg
antifelin
igm
polyclon
antiserum
conjug
fluorescein
isothiocyan
vmrd
inc
pullman
wa
usa
use
twofold
dilut
studi
control
serum
sampl
prepar
phosphat
buffer
salin
pb
start
endpoint
titer
sampl
independ
examin
two
author
alway
agre
result
show
either
cytoplasm
membran
fluoresc
consid
posit
due
lack
serum
sampl
known
seroposit
cat
onset
studi
serum
sampl
dog
leishmaniosi
ifat
titer
use
posit
control
subject
interpret
ifat
n
studi
control
sera
randomli
select
aid
excel
random
number
gener
examin
second
time
antileishmania
igg
examin
awar
origin
sampl
sampl
examin
previous
describ
elisa
methodolog
solanogallego
et
al
modif
sherri
et
al
employ
measur
antileishmania
igg
group
group
b
control
serum
sampl
use
solubl
antigen
l
infantum
strain
use
ifat
alkalin
phosphataseconjug
goat
anticat
igg
jackson
immunoresearch
laboratori
inc
west
grove
pa
usa
sampl
test
duplic
averag
optic
densiti
od
sampl
calcul
felv
antigen
antifiv
antibodi
detect
serum
sampl
group
group
b
cat
use
commerci
kit
snap
fiv
antibodyfelv
antigen
combo
test
idexx
laboratori
westbrook
usa
serolog
antifcv
igg
antit
gondii
igg
antit
gondii
igm
antib
hensela
igg
perform
sampl
use
commerci
ifat
kit
fuller
laboratori
fullerton
ca
usa
interpret
use
cutoff
valu
propos
manufactur
respect
repeat
ifat
agreement
proport
posit
result
ifat
elisa
antileishmania
igg
ifat
pcr
elisa
pcr
evalu
mcnemar
test
symmetri
possibl
associ
result
ifat
antileishmania
igg
breed
sex
length
haircoat
live
condit
health
statu
season
sampl
seroposit
group
group
b
cat
infecti
agent
examin
use
pearson
test
fisher
exact
test
wherea
independ
sampl
ttest
use
examin
possibl
associ
result
ifat
antileishmania
igg
age
cat
diagnost
perform
ifat
possibl
cutoff
titer
evalu
calcul
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
youden
index
ie
sensit
specif
use
infect
statu
cat
ie
result
pcr
blood
skin
biopsi
bone
marrow
conjunctiva
gold
standard
diagnost
perform
elisa
possibl
cutoff
od
lie
higher
valu
studi
cat
averag
od
control
cat
examin
receiv
oper
characterist
roc
curv
analysi
calcul
area
curv
auc
level
signific
set
analysi
perform
stata
stata
corp
sampl
perform
may
decemb
cat
rest
year
remain
signal
live
condit
group
group
b
cat
clinic
sign
group
b
cat
final
diagnos
previous
report
chatzi
et
al
none
group
b
cat
diagnos
leishmaniosi
base
result
pcr
cat
group
group
b
cat
infect
l
infantum
wherea
remain
cat
noninfect
chatzi
et
al
sinc
none
control
serum
sampl
react
even
lowest
dilut
cutoff
valu
ifat
antileishmania
igg
antileishmania
igm
establish
signific
agreement
first
second
ifat
antileishmania
igg
randomli
select
group
group
b
control
serum
sampl
p
sampl
neg
one
posit
first
run
neg
ifat
repeat
averag
elisa
od
standard
deviat
sd
control
serum
sampl
respect
consequ
cutoff
od
establish
averag
sd
wherea
result
averag
sd
consid
equivoc
solanogallego
et
al
low
ifat
titer
antileishmania
igg
detect
studi
cat
titer
two
cat
eight
cat
includ
five
group
five
group
b
cat
sampl
may
decemb
n
rest
year
n
elisa
antileishmania
igg
posit
one
cat
od
cutoff
od
equivoc
anoth
cat
od
cat
belong
group
ifatneg
sampl
may
march
respect
ifat
antileishmania
igm
posit
titer
one
group
cat
sampl
januari
also
ifatposit
antileishmania
igg
antibodi
disagr
result
ifat
elisa
antileishmania
igg
p
ifat
antileishmania
igg
pcr
p
elisa
pcr
p
ifat
antileishmania
igm
pcr
p
supplementari
tabl
diagnost
sensit
serolog
test
use
pcr
gold
standard
low
although
specif
elisa
ifat
antileishmania
igm
tabl
effort
assess
whether
cutoff
titer
respons
low
sensit
ifat
sensit
specif
ppv
npv
youden
index
recalcul
possibl
cutoff
tabl
base
result
highest
youden
index
ifat
antileishmania
igg
achiev
use
cutoff
titer
wherea
cutoff
titer
appli
studi
correspond
highest
youden
index
ifat
antileishmania
igm
regard
elisa
antileishmania
igg
appreci
improv
diagnost
accuraci
could
achiev
modifi
cutoff
od
sinc
auc
fig
signific
associ
result
ifat
antileishmania
igg
signal
live
condit
season
sampl
supplementari
tabl
group
group
b
group
b
cat
group
cat
p
presenc
clinic
sign
may
compat
felin
leishmaniosi
group
b
cat
supplementari
tabl
seroposit
infecti
agent
examin
group
group
b
group
b
cat
supplementari
tabl
inclus
criteria
cat
older
year
without
histori
leishmaniosi
administr
drug
elig
lack
differ
seroposit
rate
group
b
denot
result
studi
may
applic
gener
felin
popul
irrespect
signal
live
condit
season
sampl
clinic
statu
dog
crosssect
serolog
survey
provid
estim
true
preval
infect
l
infantum
preval
diseas
mani
infect
healthi
dog
seroconvert
wherea
almost
diseas
dog
seroposit
leontid
et
al
saridomichelaki
clinic
mancianti
solanogallego
et
al
experiment
kirkpatrick
et
al
evid
cat
less
suscept
l
infantum
dog
thu
proport
infect
cat
high
antibodi
titer
clinic
sign
leishmaniosi
expect
lower
dog
moreno
et
al
vita
et
al
explain
low
sensit
serolog
detect
infect
rel
low
ifat
titer
elisa
od
found
five
one
infect
cat
studi
respect
posit
result
ifat
five
cat
pcrneg
consid
falseposit
lack
agreement
ifat
elisa
antileishmania
igg
also
report
investig
sobrinho
et
al
strengthen
option
suggest
falseposit
due
technic
reason
rather
due
crossreact
latter
expect
preferenti
affect
ifat
elisa
despit
adequ
repeat
ifat
interpret
subject
low
serum
dilut
posit
sampl
remnant
dye
may
misidentifi
dull
cytoplasm
fluoresc
altern
explan
could
ifatposit
pcrneg
cat
previous
expos
l
infantum
develop
specif
igg
still
detect
although
infect
selfclear
et
al
although
increas
preval
posit
pcr
sandfli
period
chatzi
et
al
favor
option
explain
neg
result
elisa
cat
serolog
survey
felin
leishmaniosi
carri
area
canin
andor
human
infect
l
infantum
endem
reveal
wide
rang
seropreval
rate
among
differ
countri
also
differ
area
countri
vita
et
al
eg
portug
duart
et
al
maia
et
al
spain
ayllon
et
al
et
al
et
al
moreno
et
al
itali
pennisi
poli
et
al
brazil
bresciani
et
al
et
al
strike
variat
may
due
vectorandor
reservoirrel
factor
moreno
et
al
also
attribut
differ
among
studi
serolog
test
et
al
solanogallego
et
al
cutoff
valu
coelho
et
al
da
silva
et
al
et
al
felin
popul
screen
et
al
poli
et
al
result
underlin
signific
serolog
test
seropreval
base
ifat
base
elisa
select
cutoff
valu
moreno
et
al
outcom
studi
tabl
sensit
specif
posit
predict
valu
ppv
neg
predict
valu
npv
youden
index
differ
cutoff
titer
ifat
antileishmania
igg
igm
antibodi
elisa
antileishmania
igg
antibodi
clinic
normal
n
sick
n
cat
diagnosi
infect
l
infantum
pcr
blood
skin
biopsi
bone
marrow
andor
conjunctiva
gold
standard
separ
infect
noninfect
cat
sensit
ci
specif
ci
ppv
ci
npv
ci
youden
index
ifat
employ
serolog
survey
canin
leishmaniosi
cutoff
valu
may
establish
base
titer
nonendem
control
popul
distribut
titer
known
posit
neg
serum
sampl
quinnel
et
al
sinc
latter
possibl
case
ifat
cutoff
titer
establish
use
serum
sampl
nonendem
control
cat
similar
popul
characterist
studi
cat
felin
infect
dermotrop
leishmania
speci
report
texa
craig
et
al
trainor
et
al
typic
associ
seroconvers
sinc
none
cat
present
cutan
leishmaniosi
ifat
cutoff
titer
establish
low
believ
cat
leishmaniaspecif
antibodi
also
higher
ifat
cutoff
titer
antileishmania
igg
ie
could
slightli
increas
specif
expens
sensit
addit
roc
curv
analysi
result
elisa
show
propos
methodolog
select
cutoff
od
solanogallego
et
al
ideal
avoid
falseposit
result
survey
signal
live
condit
cat
found
associ
ifat
seroposit
also
case
previou
studi
ayllon
et
al
coelho
et
al
diakou
et
al
et
al
nasereddin
et
al
sarkari
et
al
solanogallego
et
al
one
except
cardoso
et
al
result
serolog
may
fluctuat
time
vita
et
al
least
dog
seroposit
rate
usual
increas
transmiss
period
et
al
greec
usual
extend
april
novemb
chanioti
et
al
sinc
certain
time
period
need
develop
igg
exposur
infecti
agent
compar
seroposit
rate
period
start
end
month
later
transmiss
period
ie
may
decemb
rest
year
differ
found
previou
investig
disclos
associ
clinic
statu
cat
healthi
sick
presenc
variou
clinic
sign
result
serolog
et
al
ayllon
et
al
cardoso
et
al
et
al
solanogallego
et
al
apart
one
studi
skin
lesion
compat
leishmaniosi
risk
factor
seroposit
sherri
et
al
studi
similar
seropreval
group
b
lack
associ
clinic
sign
group
b
result
ifat
igg
could
attribut
natur
resist
cat
l
infantum
also
confound
effect
falseposit
result
ifat
latter
strengthen
signific
associ
posit
pcr
presenc
least
one
system
sign
compat
felin
leishmaniosi
previous
shown
group
b
cat
chatzi
et
al
retrovir
infect
may
downregul
immun
respons
infect
cat
thu
increas
suscept
leishmaniosi
leiva
et
al
maroli
et
al
vide
et
al
risk
seroposit
pennisi
sherri
et
al
lack
associ
felv
fiv
infect
seroposit
confirm
previou
observ
et
al
ayllon
et
al
coelho
et
al
et
al
et
al
solanogallego
et
al
vita
et
al
true
fcv
gondii
cardoso
et
al
coelho
et
al
et
al
nasereddin
et
al
solanogallego
et
al
wherea
lack
b
hensela
seroposit
previous
demonstr
presenc
antileishmania
igm
previous
investig
cat
dog
natur
experiment
activ
diseas
leishmaniaspecif
igm
may
present
although
lower
frequenc
compar
igg
de
freita
et
al
rei
et
al
et
al
et
al
rodriguez
et
al
consid
marker
acut
infect
et
al
may
true
cat
sinc
igmposit
cat
pcrposit
sampl
long
transmiss
period
ifat
elisa
antileishmania
igg
character
low
sensit
high
specif
detect
infect
cat
diagnost
perform
substanti
improv
chang
cutoff
valu
although
diagnost
test
elisa
antileishmania
igg
ifat
antileishmania
igm
valuabl
result
posit
due
high
specif
suitabl
epidemiolog
survey
felin
infect
l
infantum
due
low
sensit
research
cofinanc
european
union
european
social
fund
esf
greek
nation
fund
oper
program
educ
lifelong
learn
nation
strateg
refer
framework
nsrf
research
fund
program
heracleitu
ii
invest
knowledg
societi
european
social
fund
fund
sourc
involv
studi
design
collect
analysi
interpret
data
write
report
decis
submit
articl
public
